202 related articles for article (PubMed ID: 10673751)
21. [Identification of immunoglobulin and T-cell receptor gene rearrangements--prerequisite for monitoring of minimal residual disease in Polish acute lymphoblastic leukemia patients based on European standards. Preliminary results].
Dawidowska M; Derwich K; Szczepański T; Jółkowska J; Witt M; Wachowiak J
Med Wieku Rozwoj; 2006; 10(1 Pt 2):323-34. PubMed ID: 17028396
[TBL] [Abstract][Full Text] [Related]
22. Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL).
Shahkarami S; Mehrasa R; Younesian S; Yaghmaie M; Chahardouli B; Vaezi M; Rezaei N; Nikbakht M; Alimoghaddam K; Ghavamzadeh A; Tavakkoly-Bazzaz J; Ghaffari SH
Ann Hematol; 2018 Apr; 97(4):585-595. PubMed ID: 29392424
[TBL] [Abstract][Full Text] [Related]
23. [A tal-1 deletion as real-time quantitative polymerase chain reaction target for detection of minimal residual disease in T-lineage acute lymphoblastic leukemia].
Wang L; Zhang LP; Li ZG; Cheng YF; Tian KG; Lu AD
Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):170-3. PubMed ID: 15833185
[TBL] [Abstract][Full Text] [Related]
24. IgH/TCR delta PCR oligonucleotide liquid hybridization, a fast and sensitive assay for monitoring minimal residual disease in childhood B-precursor ALL.
Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; von dem Borne AE; van der Schoot CE
Leukemia; 1995 Jan; 9(1):216-22. PubMed ID: 7845021
[TBL] [Abstract][Full Text] [Related]
25. Consensus JH gene probes with conjugated 3'-minor groove binder for monitoring minimal residual disease in acute lymphoblastic leukemia.
Uchiyama M; Maesawa C; Yashima-Abo A; Tarusawa M; Endo M; Sugawara W; Chida S; Onodera S; Tsukushi Y; Ishida Y; Tsuchiya S; Masuda T
J Mol Diagn; 2005 Feb; 7(1):121-6. PubMed ID: 15681483
[TBL] [Abstract][Full Text] [Related]
26. MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR.
van der Velden VH; van Dongen JJ
Methods Mol Biol; 2009; 538():115-50. PubMed ID: 19277574
[TBL] [Abstract][Full Text] [Related]
27. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL.
Garand R; Beldjord K; Cavé H; Fossat C; Arnoux I; Asnafi V; Bertrand Y; Boulland ML; Brouzes C; Clappier E; Delabesse E; Fest T; Garnache-Ottou F; Huguet F; Jacob MC; Kuhlein E; Marty-Grès S; Plesa A; Robillard N; Roussel M; Tkaczuk J; Dombret H; Macintyre E; Ifrah N; Béné MC; Baruchel A
Leukemia; 2013 Feb; 27(2):370-6. PubMed ID: 23070018
[TBL] [Abstract][Full Text] [Related]
28. Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia.
Denys B; van der Sluijs-Gelling AJ; Homburg C; van der Schoot CE; de Haas V; Philippé J; Pieters R; van Dongen JJ; van der Velden VH
Leukemia; 2013 Mar; 27(3):635-41. PubMed ID: 22945774
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E
N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378
[TBL] [Abstract][Full Text] [Related]
30. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia.
Flohr T; Schrauder A; Cazzaniga G; Panzer-Grümayer R; van der Velden V; Fischer S; Stanulla M; Basso G; Niggli FK; Schäfer BW; Sutton R; Koehler R; Zimmermann M; Valsecchi MG; Gadner H; Masera G; Schrappe M; van Dongen JJ; Biondi A; Bartram CR;
Leukemia; 2008 Apr; 22(4):771-82. PubMed ID: 18239620
[TBL] [Abstract][Full Text] [Related]
31. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous detection and quantification of minimal residual disease in childhood acute lymphoblastic leukaemia using real-time polymerase chain reaction.
Kwan E; Norris MD; Zhu L; Ferrara D; Marshall GM; Haber M
Br J Haematol; 2000 May; 109(2):430-4. PubMed ID: 10848837
[TBL] [Abstract][Full Text] [Related]
33. Sequential monitoring of minimal residual disease in acute lymphoblastic leukemia: 7-year experience in a pediatric hematology/oncology unit.
Katsibardi K; Moschovi MA; Braoudaki M; Papadhimitriou SI; Papathanasiou C; Tzortzatou-Stathopoulou F
Leuk Lymphoma; 2010 May; 51(5):846-52. PubMed ID: 20350276
[TBL] [Abstract][Full Text] [Related]
34. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.
van der Velden VH; Cazzaniga G; Schrauder A; Hancock J; Bader P; Panzer-Grumayer ER; Flohr T; Sutton R; Cave H; Madsen HO; Cayuela JM; Trka J; Eckert C; Foroni L; Zur Stadt U; Beldjord K; Raff T; van der Schoot CE; van Dongen JJ;
Leukemia; 2007 Apr; 21(4):604-11. PubMed ID: 17287850
[TBL] [Abstract][Full Text] [Related]
35. Advanced Minimal Residual Disease Monitoring for Acute Lymphoblastic Leukemia with Multiplex Mediator Probe PCR.
Kipf E; Schlenker F; Borst N; Fillies M; Kirschner-Schwabe R; Zengerle R; Eckert C; von Stetten F; Lehnert M
J Mol Diagn; 2022 Jan; 24(1):57-68. PubMed ID: 34757015
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
[TBL] [Abstract][Full Text] [Related]
37. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction.
Brisco MJ; Condon J; Hughes E; Neoh SH; Sykes PJ; Seshadri R; Toogood I; Waters K; Tauro G; Ekert H
Lancet; 1994 Jan; 343(8891):196-200. PubMed ID: 7904666
[TBL] [Abstract][Full Text] [Related]
38. Results of minimal residual disease (MRD) evaluation and MRD-based treatment stratification in childhood ALL.
Cazzaniga G; d'Aniello E; Corral L; Biondi A
Best Pract Res Clin Haematol; 2002 Dec; 15(4):623-38. PubMed ID: 12617867
[TBL] [Abstract][Full Text] [Related]
39. Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR.
van der Velden VH; Willemse MJ; van der Schoot CE; Hählen K; van Wering ER; van Dongen JJ
Leukemia; 2002 May; 16(5):928-36. PubMed ID: 11986956
[TBL] [Abstract][Full Text] [Related]
40. Molecular detection of acute lymphoblastic leukaemia in boys with testicular relapse.
Lal A; Kwan E; al Mahr M; Zhou L; Ferrara D; Tobias V; O'Gorman Hughes D; Haber M; Norris MD; Marshall GM
Mol Pathol; 1998 Oct; 51(5):277-81. PubMed ID: 10193523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
